Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net (Tables)

v3.19.1
Intangibles, net (Tables)
 3 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The table below provides a summary of the JMC intangible asset as of March 31, 2019 and December 31, 2018, respectively:
 
 
 
Estimated Useful
 
 
March 31,
 
 
December

31,
 
($ in thousands)
 
Lives (in years)
 
 
2019
 
 
2018
 
Ceracade®
 
 
3
 
 
$
300
 
 
$
300
 
Luxamend®
 
 
3
 
 
 
50
 
 
 
50
 
Targadox®
 
 
3
 
 
 
1,250
 
 
 
1,250
 
Exelderm®
 
 
3
 
 
 
1,200
 
 
 
1,200
 
Total
 
 
 
 
 
 
2,800
 
 
 
2,800
 
Accumulated amortization
 
 
 
 
 
 
1,617
 
 
 
1,383
 
Net intangible assets
 
 
 
 
 
$
1,183
 
 
$
1,417
 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class
The table below provides a summary for the three months ended March 31, 2019, of JMC recognized expense related to its product licenses, which was recorded in costs of goods sold on the Condensed Consolidated Statement of Operations:
 
(
$ in thousands)
 
Intangible
 
Assets
 
 
Beginning balance at January 1, 2019
 
$
1,417
 
Amortization expense
 
 
(234
)
Ending balance at March 31, 2019
 
$
1,183
 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The future amortization of these intangible assets is as follows:
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
($ in thousands)
 
Ceracade®
 
 
Targadox®
 
 
Exelderm®
 
 
Amortization
 
For the nine-months ending December 31, 2019
 
$
8
 
 
$
208
 
 
$
300
 
 
$
516
 
December 31, 2020
 
 
–
 
 
 
–
 
 
 
400
 
 
 
400
 
December 31, 2021
 
 
–
 
 
 
–
 
 
 
267
 
 
 
267
 
Total
 
$
8
 
 
$
208
 
 
$
967
 
 
$
1,183